AC Immune SA
ACIU
$2.96
$0.010.34%
NASDAQ
| 12/31/2025 | 06/30/2025 | 03/31/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -67.32% | 108.40% | -- | -- | -92.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -67.32% | 108.40% | -- | -- | -92.25% |
| Cost of Revenue | -26.02% | 7.63% | 2.07% | 2.07% | 8.69% |
| Gross Profit | 22.82% | -3.42% | 4.27% | 4.27% | -9,507.78% |
| SG&A Expenses | 15.72% | -6.15% | -13.07% | -13.07% | -0.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -474.84% | 25.17% | 101.41% | 101.41% | 96.03% |
| Total Operating Expenses | -17.96% | 4.79% | -1.33% | -1.33% | 8.60% |
| Operating Income | 14.95% | -1.40% | 6.12% | 6.12% | -430.15% |
| Income Before Tax | -0.03% | -2.06% | -3.61% | -3.61% | -235.76% |
| Income Tax Expenses | -- | -- | -- | -- | 209.09% |
| Earnings from Continuing Operations | -0.01% | -2.06% | -3.61% | -3.61% | -235.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.01% | -2.06% | -3.61% | -3.61% | -235.75% |
| EBIT | 14.95% | -1.40% | 6.12% | 6.12% | -430.15% |
| EBITDA | 15.25% | -1.33% | 6.05% | 6.05% | -489.32% |
| EPS Basic | 1.06% | -0.99% | -2.53% | -2.53% | -191.10% |
| Normalized Basic EPS | 0.98% | -0.95% | -2.57% | -2.57% | -191.19% |
| EPS Diluted | 2.68% | -0.99% | -2.53% | -2.53% | -195.95% |
| Normalized Diluted EPS | 0.98% | -0.95% | -2.57% | -2.57% | -191.19% |
| Average Basic Shares Outstanding | 1.08% | 1.09% | 1.03% | 1.03% | 15.27% |
| Average Diluted Shares Outstanding | 1.08% | 1.09% | 1.03% | 1.03% | 15.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |